Table 2.
Characteristics of patients with IPF at the time of SLB
| All | Acute exacerbation | No acute exacerbation | |
|---|---|---|---|
| Subjects | 152 | 41 | 111 |
| Case or control months | 5,783 | 41 | 5,742 |
| Age (years) | 65 [61–70] | 68 [63–71] | 65 [60–70] |
| Male | 106 (70%) | 29 (71%) | 77 (69%) |
| Pack-years | 30 [0–45] | 30 [0–53] | 26 [0–45] |
| Pulmonary function tests | |||
| FVC (% predicted) | 83.9 [75.1–96.4] | 83.6 [75–92.2] | 85.2 [75.2–97.2] |
| DLCO (% predicted) | 71.6 [55.5–85.6] | 61.0 [48.5–75.9] | 74.8 [57.2–88.4] |
| HRCT pattern | |||
| UIP | 23 (15%) | 9 (22%) | 14 (13%) |
| Possible UIP | 122 (80%) | 30 (73%) | 92 (83%) |
| Inconsistent with UIP | 7 (5%) | 2 (5%) | 5 (4%) |
| Antifibrotic therapy | |||
| Pirfenidone | 55 (36%) | 18 (44%) | 37 (33%) |
| Nintedanib | 19 (13%) | 3 (7%) | 16 (14%) |
Data presented as median [interquartile rage] or frequencies (%)
IPF idiopathic pulmonary fibrosis, SLB surgical lung biopsy, FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, HRCT high-resolution computed tomography